The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 09, 2024
Filed:
Nov. 05, 2020
Applicant:
Cormatrix Cardiovascular, Inc., Roswell, GA (US);
Inventor:
Robert G Matheny, Norcross, GA (US);
Assignee:
CorMatrix Cardiovascular, Inc., Roswell, GA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61L 27/36 (2006.01); A61F 2/00 (2006.01); A61K 31/4418 (2006.01); A61L 27/34 (2006.01); A61L 27/38 (2006.01); A61L 27/54 (2006.01); A61L 27/58 (2006.01); A61F 2/06 (2013.01); A61L 27/50 (2006.01);
U.S. Cl.
CPC ...
A61L 27/3633 (2013.01); A61F 2/00 (2013.01); A61F 2/0095 (2013.01); A61F 2/06 (2013.01); A61K 31/4418 (2013.01); A61L 27/34 (2013.01); A61L 27/3834 (2013.01); A61L 27/507 (2013.01); A61L 27/54 (2013.01); A61L 27/58 (2013.01); A61F 2210/0004 (2013.01); A61F 2250/0067 (2013.01); A61L 2300/414 (2013.01); A61L 2430/20 (2013.01);
Abstract
Cardiovascular prostheses for treating, reconstructing and replacing damaged or diseased cardiovascular tissue that include particulate structures that are formed from PGS, cerivastatin and everolimus. The particulate structures are configured to modulate inflammation of damaged cardiovascular tissue in vivo by increasing expression of Kruppel like factor 2 (KLF-2), whereby localized expression of monocyte chemoattractant protein 1 (MCP-1) and C-C chemokine receptor type 2 (CCR2) is inhibited at transcriptional and translational levels as a function of the KLF-2 modulation.